Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

AbbVie Inc., consolidated cash flow statement

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net earnings	4,873)	11,845)	11,549)	4,622)	7,882)
Depreciation	752)	778)	803)	666)	464)
Amortization of intangible assets	7,946)	7,689)	7,718)	5,805)	1,553)
Deferred income taxes	(2,889)	(1,931)	(898)	(2,325)	122)
Change in fair value of contingent consideration liabilities	5,128)	2,761)	2,679)	5,753)	3,091)
Payments of contingent consideration liabilities	(870)	(164)	(91)	—)	—)
Stock-based compensation	747)	671)	692)	753)	430)
Acquired IPR&D and milestones	778)	697)	1,124)	1,376)	490)
Other charges related to collaborations	—)	—)	500)	—)	—)
Gain on divestitures	—)	(172)	(68)	—)	(330)
Non-cash litigation reserve adjustments, net of cash payments	(443)	2,243)	163)	(31)	—)
Impairment of intangible assets	4,229)	770)	50)	—)	1,030)
Other, net	(225)	(150)	(213)	863)	43)
Accounts receivable	66)	(1,455)	(1,321)	(929)	(74)
Inventories	(417)	(686)	(142)	(40)	(231)
Prepaid expenses and other assets	(188)	(264)	(197)	134)	(225)
Accounts payable and other liabilities	3,840)	1,769)	1,719)	1,514)	97)
Income tax assets and liabilities, net	(488)	542)	(1,290)	(573)	(1,018)
Changes in operating assets and liabilities, net of acquisitions	2,813)	(94)	(1,231)	106)	(1,451)
Adjustments to reconcile net earnings to net cash from operating activities	17,966)	13,098)	11,228)	12,966)	5,442)
Cash flows from operating activities	22,839)	24,943)	22,777)	17,588)	13,324)
Acquisition of businesses, net of cash acquired	—)	(255)	(525)	(38,260)	—)
Other acquisitions and investments	(1,223)	(539)	(1,377)	(1,350)	(1,135)
Acquisitions of property and equipment	(777)	(695)	(787)	(798)	(552)
Purchases of investment securities	(77)	(1,438)	(119)	(61)	(583)
Sales and maturities of investment securities	55)	1,530)	98)	1,525)	2,699)
Other, net	13)	774)	366)	1,387)	167)
Cash flows from investing activities	(2,009)	(623)	(2,344)	(37,557)	596)
Net change in commercial paper borrowings	—)	—)	—)	—)	(699)
Repayments of other short-term borrowings	—)	—)	—)	—)	(3,000)
Proceeds from issuance of long-term debt	—)	2,000)	1,000)	3,000)	31,482)
Repayments of long-term debt and finance lease obligations	(4,149)	(14,433)	(9,414)	(5,683)	(1,536)
Debt issuance costs	(38)	—)	—)	(20)	(424)
Dividends paid	(10,539)	(10,043)	(9,261)	(7,716)	(6,366)
Purchases of treasury stock	(1,972)	(1,487)	(934)	(978)	(629)
Proceeds from the exercise of stock options	180)	262)	244)	209)	8)
Payments of contingent consideration liabilities	(752)	(1,132)	(698)	(321)	(163)
Other, net	48)	30)	24)	8)	35)
Cash flows from financing activities	(17,222)	(24,803)	(19,039)	(11,501)	18,708)
Effect of exchange rate changes on cash and equivalents	5)	(62)	(97)	(5)	7)
Net change in cash and equivalents	3,613)	(545)	1,297)	(31,475)	32,635)
Cash and equivalents, beginning of year	9,201)	9,746)	8,449)	39,924)	7,289)
Cash and equivalents, end of year	12,814)	9,201)	9,746)	8,449)	39,924)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Cash flow statement item	Description	The company
Cash flows from operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	AbbVie Inc. cash flows from operating activities increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Cash flows from investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	AbbVie Inc. cash flows from investing activities increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Cash flows from financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	AbbVie Inc. cash flows from financing activities decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.

AbbVie Inc. (NYSE:ABBV)

Cash Flow Statement